Genmab — April 2018
-
Tisotumab Vedotin mention in the Seattle Genetics Q1 2018 Results http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2345077
-
" Tisotumab Vedotin (TV) Program Activities
Planned Pivotal Trial Initiation: Seattle Genetics and Genmab plan to advance TV into a pivotal phase 2 trial for recurrent or metastatic cervical cancer that relapses or progresses after standard of care treatment for cervical cancer. The single-arm trial is designed to enroll approximately 100 women and could potentially support registration under the FDA’s accelerated approval regulations.
-
The trial is expected to begin in the first half of 2018".
-
"Expanding Clinical Development Program: Seattle Genetics and Genmab plan to initiate in 2018 a phase 2 trial of TV as part of a combination regimen in women with first-line metastatic cervical cancer. In addition, a phase 2 trial is expected to begin in 2018 to evaluate TV monotherapy in a range of other solid tumors"
. -
Thanks E L
-
also the Earnings Call Transcript for those interested - https://seekingalpha.com/article/4166737-seattle-genetics-sgen-q1-2018-results-earnings-call-transcript?part=single - doesnt say much more, except that they work closely with Genmab, have visited them and that they think they will accrue the trials very rapidly and then get data 'very fast'.
-
Der forskes en del i målrettet actinium 225 terapi - ikke mindst i prostata cancer. https://www.sciencedaily.com/releases/2017/10/171003111051.htm Men også i MM kører der kliniske forsøg. F.eks. Lintuzumab (cd33) koblet med Ac225. https://www.clinicaltrials.gov/ct2/show/NCT02998047?term=actinium&rank=2
-
Problemet med dara og Ac225 kan være, at cd38 er udtrykt mange steder i kroppen, og at bivirkninger derfor vil være tunge. Derfor vil den stærke effekt af koblingen, som de prækliniske studier antyder, nok mest være eftertragtet af sen stadie patienter.
-
Article in the Neurology magazine on the MIRROR study (Ofa/MS) http://n.neurology.org/content/early/2018/04/25/WNL.0000000000005516
-
That's exactly the question. The other day Sukkeralf linked to this phase 2 study-result of ublituximab https://www.firstwordpharma.com/node/1559279?tsid=1 I don't have the knowledge to compare. Maybe others have?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind